HIGHLIGHTS
- who: Gastric cancer Second-line therapy et al. from the Division of Oncology and Hematology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea Kong, People`s Republic of China have published the paper: A phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapy, in the Journal: (JOURNAL)
- what: The present phase II study was designed to evaluate the efficacy and safety of single-agent ixabepilone in Asian patients with advanced gastric adenocarcinomas in which prior fluoropyrimidine-based therapy had failed. The aim was . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.